Skip to content
Study details
Enrolling now

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Yale University
NCT IDNCT07040592ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

30

Study length

about 1.6 years

Ages

18–99

Locations

1 site in GA

What this study is about

Researchers are testing if semaglutide, a medication used to treat alcohol use disorder (AUD), can help reduce alcohol consumption in people with HIV and AUD. The trial will last about 592 days and involve approximately 30 participants.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take semaglutide

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

semaglutide (GLP-1 agonist; stimulates insulin release)

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Safety of study assessed by adverse event reporting

Body systems

Psychiatry / Mental Health, Immune, Infectious